Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAP3K8 | P41279 | 2/20 | 0.49 |
| ▸ | CCNC | P24863 | 1/20 | 0.49 |
| ▸ | CDK8 | P49336 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ADH5 | P11766 | 1/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5607371 | 0.79 | KDM4E (0.52) | XDHALDH1A1MAP3K8CYP2C9GAA | |
| SCHEMBL5607415 | 0.76 | AR (0.40) | XDHCYP2C9GAAKMT2A | |
| SCHEMBL16309243 | 0.76 | AR (0.54) | ALDH1A1KMT2A | |
| SCHEMBL2667739 | 0.74 | ADH5 (0.75) | XDHALDH1A1TP53CYP2C9CYP19A1 | |
| SCHEMBL5606572 | 0.74 | AR (0.40) | XDHTP53KMT2A | |
| SCHEMBL762116 | 0.73 | ADH5 (0.79) | XDHALDH1A1TP53CYP2C9CYP19A1 | |
| SCHEMBL5607695 | 0.72 | KDM4E (0.65) | XDHALDH1A1CYP2C9CYP2C19GAA | |
| SCHEMBL12386586 | 0.70 | AR (0.49) | ALDH1A1CYP2C9CYP2C19KMT2AL3MBTL1 | |
| SCHEMBL5607469 | 0.70 | TEAD4 (0.57) | ALDH1A1 | |
| SCHEMBL5606163 | 0.70 | SMN1; SMN2 (0.57) | ALDH1A1TP53GAAKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1838300-A2 | 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | Emergent Product Development Gaithersburg Inc. (US) | 2007-10-03 | — | — | EP | claimed |
| US-20060211697-A1 | 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG, INC. | 2006-09-21 | — | — | US | claimed |
| WO-2006071471-A2 | 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2006-07-06 | — | — | WO | claimed |
| EP-1838300-A2 | 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | Emergent Product Development Gaithersburg Inc. (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20060211697-A1 | 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006071471-A2 | 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211697-A1 | 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents | TYR, NFE2L2, CYP1A1 | XDH 236/4885ALDH1A1 1406/4885MAP3K8 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.